+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hyperpigmentation Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4852059
  • Report
  • July 2018
  • Region: Global
  • 201 pages
  • Transparency Market Research
1 of 2

Global Hyperpigmentation Disorders Treatment Market: Overview

This report analyzes the global hyperpigmentation disorders treatment market in terms of its current and future scenario. Rise in investment in R&D of novel advanced technologies, decrease in social taboos regarding pigmentation, increase in prevalence of hyperpigmentation-related disorders, and rise in awareness about skin rejuvenation and treatment options are likely to drive the growth of the global market during the forecast period. Anti-pigmentation therapies can be classified as topical drugs, microdermabrasion, chemical peels, and laser therapy. These therapies are available in hospitals and aesthetic clinics & dermatology centers.

This report on the global hyperpigmentation disorders treatment market comprises an elaborate executive summary, including a market snapshot that provides information about various segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on product type, application, and geography. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of geography, and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global hyperpigmentation disorders treatment market.

Global Hyperpigmentation Disorders Treatment Market: Key Segments

The global hyperpigmentation disorders treatment market has been segmented into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others, based on treatment type. By disease indication, the market has been classified into melasma, post-inflammatory hyperpigmentation, solar lentigines, and others. In terms of end-user, the market has been segmented into hospitals, aesthetic clinics & dermatology centers, and others. The global hyperpigmentation disorders treatment market has been analyzed based on increasing prevalence of hyperpigmentation disorders, technology trend, expenditure on emerging technologies, and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2016 to 2026, along with their respective CAGR for the forecast period, i.e. from 2018 to 2026, considering 2017 as the base year.

Global Hyperpigmentation Disorders Treatment Market: Regional Outlook

Geographically, the global hyperpigmentation disorders treatment market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, Israel, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period of 2016 to 2026, along with their respective CAGR for the forecast period, viz. 2018-2026, considering 2017 as the base year. This report also covers the competitive scenario of the market in these regions.

Companies Mentioned in Report

The report profiles the major players operating in the global hyperpigmentation disorders treatment market in terms of attributes, such as, company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report are Bayer AG, ALLERGAN, Galderma S.A., SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC, and Vivier Pharma.

Note: Product cover images may vary from those shown
2 of 2
Section 01: Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights

Section 02: Assumptions and Research Methodology

2.1 Assumptions
2.2 Research Methodology

Section 03: Executive Summary
3.1 Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) and Distribution by Geography, 2017 and 2026
3.2 Global Hyperpigmentation Disorders Treatment Market Snapshot, 2017
3.3 Global Hyperpigmentation Disorders Treatment Market: Opportunity Map

Section 04: Market Overview
4.1 Overview
4.2 Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, 2016-2026
4.3 Global Hyperpigmentation Disorders Treatment Market Outlook
4.4 Global Hyperpigmentation Disorders Treatment Market: Porter’s Five Forces Analysis
4.5 Hyperpigmentation Disorders Treatment Market: Pipeline Analysis
4.6 Key Partnership & Acquisitions
4.7 Policies and Regulations: By Region
4.8 Disease Prevalence and Incidence Rate Globally
4.9 Global Hyperpigmentation Disorders Treatment Market: Pricing Assessment

Section 05: Market Dynamics
5.1 Drivers
5.2 Restraints
5.3 Opportunity Analysis
5.4 Opportunities
5.5 Trends

Section 06: Global Hyperpigmentation Disorders Treatment Market Analysis, by Treatment Type
6.1 Introduction
6.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Treatment Type
6.3 Hyperpigmentation Disorders Treatment Market Analysis, by Treatment Type
6.3.1 Topical Drugs
6.3.2 Laser Therapy
6.3.3 Chemical Peels
6.3.4 Microdermabrasion
6.3.5 Phototherapy
6.3.6 Others
6.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment Type

Section 07: Global Hyperpigmentation Disorders Treatment Market Analysis, by Disease Indication
7.1 Introduction
7.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Disease Indication
7.3 Hyperpigmentation Disorders Treatment Market Analysis, by Disease Indication
7.3.1 Melasma
7.3.2 Post-inflammatory Hyperpigmentation
7.3.3 Solar Lentigines
7.3.4 Others
7.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Disease Indication

Section 08: Global Hyperpigmentation Disorders Treatment Market Analysis, by End-user
8.1 Introduction
8.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by End-user
8.3 Hyperpigmentation Disorders Treatment Market Analysis, by End-user
8.3.1 Hospitals
8.3.2 Aesthetic Clinics & Dermatology Centers
8.3.3 Others
8.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by End-user

Section 09: Global Hyperpigmentation Disorders Treatment Market Analysis, by Region
9.1 Global Hyperpigmentation Disorders Treatment Market Snapshot, by Country
9.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Region
9.3 Hyperpigmentation Disorders Treatment Market Forecast, by Region
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Latin America
9.3.5 Middle East & Africa
9.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Region

Section 10: North America Hyperpigmentation Disorders Treatment Market Analysis
10.1 Key Findings
10.2 North America Hyperpigmentation Disorders Treatment Market Overview
10.3 North America Market Value Share Analysis, by Treatment Type
10.4 North America Market Forecast, by Treatment Type
10.4.1 Topical Drugs
10.4.2 Laser Therapy
10.4.3 Chemical Peels
10.4.4 Microdermabrasion
10.4.5 Phototherapy
10.4.6 Others
10.5 North America Market Value Share Analysis, by Disease Indication
10.6 North America Market Forecast, by Disease Indication
10.6.1 Melasma
10.6.2 Post-inflammatory Hyperpigmentation
10.6.3 Solar Lentigines
10.6.4 Others
10.7 North America Market Value Share Analysis, by End-user
10.8 North America Market Forecast, by End-user
10.8.1 Hospitals
10.8.2 Aesthetic Clinics & Dermatology Centers
10.8.3 Others
10.9 Market Analysis, by Country
10.10 Market Value Share Analysis, by Country
10.11 Market Size (US$ Mn) Forecast, by Country, 2018-2026
10.11.1 U.S.
10.11.2 Canada
10.12 Market Attractiveness Analysis
10.12.1 By Treatment Type
10.12.2 By Disease Indication
10.12.3 By End-user
10.12.4 By Country

Section 11: Europe Hyperpigmentation Disorders Treatment Market Analysis
11.1 Key Findings
11.2 Europe Hyperpigmentation Disorders Treatment Market Overview
11.3 Europe Market Value Share Analysis, by Treatment Type
11.4 Europe Market Forecast, by Treatment Type
11.4.1 Topical Drugs
11.4.2 Laser Therapy
11.4.3 Chemical Peels
11.4.4 Microdermabrasion
11.4.5 Phototherapy
11.4.6 Others
11.5 Europe Market Value Share Analysis, by Disease Indication
11.6 Europe Market Forecast, by Disease Indication
11.6.1 Melasma
11.6.2 Post-inflammatory Hyperpigmentation
11.6.3 Solar Lentigines
11.6.4 Others
11.7 Europe Market Value Share Analysis, by End-user
11.8 Europe Market Forecast, by End-user
11.8.1 Hospitals
11.8.2 Aesthetic Clinics & Dermatology Centers
11.8.3 Others
11.9 Market Analysis, by Country
11.10 Market Value Share Analysis, by Country
11.11 Market Size (US$ Mn) Forecast, by Country, 2018-2026
11.11.1 Germany
11.11.2 France
11.11.3 U.K.
11.11.4 Italy
11.11.5 Spain
11.11.6 Rest of Europe
11.12 Market Attractiveness Analysis
11.12.1 By Treatment Type
11.12.2 By Disease Indication
11.12.3 By End-user
11.12.4 By Country

Section 12: Asia Pacific Hyperpigmentation Disorders Treatment Market Analysis
12.1 Key Findings
12.2 Asia Pacific Hyperpigmentation Disorders Treatment Market Overview
12.3 Asia Pacific Market Value Share Analysis, by Treatment Type
12.4 Asia Pacific Market Forecast, by Treatment Type
12.4.1 Topical Drugs
12.4.2 Laser Therapy
12.4.3 Chemical Peels
12.4.4 Microdermabrasion
12.4.5 Phototherapy
12.4.6 Others
12.5 Asia Pacific Market Value Share Analysis, by Disease Indication
12.6 Asia Pacific Market Forecast, by Disease Indication
12.6.1 Melasma
12.6.2 Post-inflammatory Hyperpigmentation
12.6.3 Solar Lentigines
12.6.4 Others
12.7 Asia Pacific Market Value Share Analysis, by End-user
12.8 Asia Pacific Market Forecast, by End-user
12.8.1 Hospitals
12.8.2 Aesthetic Clinics & Dermatology Centers
12.8.3 Others
12.9 Market Analysis, by Country
12.10 Market Value Share Analysis, by Country
12.11 Market Size (US$ Mn) Forecast, by Country, 2018-2026
12.11.1 China
12.11.2 Japan
12.11.3 India
12.11.4 Australia & New Zealand
12.11.5 Rest of Asia Pacific
12.12 Market Attractiveness Analysis
12.12.1 By Treatment Type
12.12.2 By Disease Indication
12.12.3 By End-user
12.12.4 By Country

Section 13: Latin America Hyperpigmentation Disorders Treatment Market Analysis
13.1 Key Findings
13.2 Latin America Hyperpigmentation Disorders Treatment Market Overview
13.3 Latin America Market Value Share Analysis, by Treatment Type
13.4 Latin America Market Forecast, by Treatment Type
13.4.1 Topical Drugs
13.4.2 Laser Therapy
13.4.3 Chemical Peels
13.4.4 Microdermabrasion
13.4.5 Phototherapy
13.4.6 Others
13.5 Latin America Market Value Share Analysis, by Disease Indication
13.6 Latin America Market Forecast, by Disease Indication
13.6.1 Melasma
13.6.2 Post-inflammatory Hyperpigmentation
13.6.3 Solar Lentigines
13.6.4 Others
13.7 Latin America Market Value Share Analysis, by End-user
13.8 Latin America Market Forecast, by End-user
13.8.1 Hospitals
13.8.2 Aesthetic Clinics & Dermatology Centers
13.8.3 Others
13.9 Market Analysis, by Country
13.10 Market Value Share Analysis, by Country
13.11 Market Size (US$ Mn) Forecast, by Country, 2018-2026
13.11.1 Brazil
13.11.2 Mexico
13.11.3 Rest of Latin America
13.12 Market Attractiveness Analysis
13.12.1 By Treatment Type
13.12.2 By Disease Indication
13.12.3 By End-user
13.12.4 By Country

Section 14: Middle East & Africa Hyperpigmentation Disorders Treatment Market Analysis
14.1 Key Findings
14.2 Middle East & Africa Hyperpigmentation Disorders Treatment Market Overview
14.3 Middle East & Africa Market Value Share Analysis, by Treatment Type
14.4 Middle East & Africa Market Forecast, by Treatment Type
14.4.1 Topical Drugs
14.4.2 Laser Therapy
14.4.3 Chemical Peels
14.4.4 Microdermabrasion
14.4.5 Phototherapy
14.4.6 Others
14.5 Middle East & Africa Market Value Share Analysis, by Disease Indication
14.6 Middle East & Africa Market Forecast, by Disease Indication
14.6.1 Melasma
14.6.2 Post-inflammatory Hyperpigmentation
14.6.3 Solar Lentigines
14.6.4 Others
14.7 Middle East & Africa Market Value Share Analysis, by End-user
14.8 Middle East & Africa Market Forecast, by End-user
14.8.1 Hospitals
14.8.2 Aesthetic Clinics & Dermatology Centers
14.8.3 Others
14.9 Market Analysis, by Country
14.10 Market Value Share Analysis, by Country
14.11 Market Size (US$ Mn) Forecast, by Country, 2018-2026
14.11.1 GCC Countries
14.11.2 South Africa
14.11.3 Rest of Middle East & Africa
14.12 Market Attractiveness Analysis
14.12.1 By Treatment Type
14.12.2 By Disease Indication
14.12.3 By End-user
14.12.4 By Country

Section 15: Competition Landscape
15.1 Competition Matrix
15.2 Hyperpigmentation Disorders Treatment Market Share Analysis, by Company (2017)
15.3 Company Profiles
15.3.1 Bayer AG
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.1.4 Strategic Overview
15.3.1.5 Financial Overview
15.3.2 ALLERGAN
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2 Product Portfolio
15.3.2.3 SWOT Analysis
15.3.2.4 Strategic Overview
15.3.2.5 Financial Overview
15.3.3 Galderma S.A. (Nestle Skin Health S.A)
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.3.4 Strategic Overview
15.3.4 SkinCeuticals
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.4.4 Strategic Overview
15.3.5 Pierre Fabre
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.5.4 Strategic Overview
15.3.5.5 Financial Overview
15.3.6 EpiPharm AG
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2 Product Portfolio
15.3.6.3 SWOT Analysis
15.3.6.4 Strategic Overview
15.3.7 RXi Pharmaceuticals Corporation
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2 Product Portfolio
15.3.7.3 SWOT Analysis
15.3.7.4 Strategic Overview
15.3.7.5 Financial Overview
15.3.8 Obagi Cosmeceuticals LLC (Obagi medical)
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2 Product Portfolio
15.3.8.3 SWOT Analysis
15.3.8.4 Strategic Overview
15.3.9 Vivier Pharma
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2 Product Portfolio
15.3.9.3 SWOT Analysis
15.3.9.4 Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll